Hemanext
Hemanext is a medical technology company that develops and sells the FDA-authorized Hemanext ONE disposable blood processing and storage system, which preserves red blood cell quality under hypoxic conditions for supply to hospital transfusion services.
- Company typePrivate
- Founded2006
- HeadquartersLexington, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Hemanext firmographics
Firmographics- Name
- Hemanext
- Legal name
- Hemanext Inc.
- Website
- https://hemanext.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Hemanext is a medical technology company that develops and sells the FDA-authorized Hemanext ONE disposable blood processing and storage system, which preserves red blood cell quality under hypoxic conditions for supply to hospital transfusion services.
- Ownership category
- akta.pro rank
Hemanext industry classification
Industry- Product category
- Blood Storage Medical Devices
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)
- akta.pro secondary industry
- Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors) (HLAAAJAC)
Keywords
Where Hemanext is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Hemanext business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Hemanext ONE Disposable Kit Sales: Hemanext sells disposable Hemanext ONE processing and storage kit sets to blood establishments (blood centers). Blood establishments use the kits to process and store hypoxic red blood cells, which are then supplied to hospitals for transfusion. The model is a pure consumables/disposables model with no upfront capital equipment required from customers. Revenue is generated per unit of disposable kit sold to blood establishments.
- Hypoxic Red Blood Cell Supply: Blood establishments (such as OneBlood and Vitalant) that produce hypoxic RBCs using Hemanext ONE supply these units to hospitals. While revenue to Hemanext comes from disposable kit sales, the end-product (oxygen-controlled RBC) is billed by blood establishments to hospitals under CMS HCPCS code P9027 at approximately $487 per unit for outpatient use — nearly 3x the rate for conventional RBC.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Hemanext ONE disposable processing kit (sold to blood establishments) |
| Unit Pricing | Pay-as-you-go | Oxygen-controlled RBC unit (CMS reimbursement) |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Hemanext product offering
Product offeringCore offering
Hemanext develops and manufactures the Hemanext ONE System, a first-in-class FDA-authorized and CE-marked disposable medical device that processes and stores red blood cells under oxygen-controlled (hypoxic) conditions. The system consists of an Oxygen Reduction Bag (ORB) that deoxygenates RBCs in approximately 3 to 3.5 hours and a Hemanext Storage Bag (HSB) that maintains hypoxic conditions throughout the 42-day refrigerated shelf life, preserving RBC metabolism, deformability, and post-transfusion recovery. The company sells disposable kits directly to blood establishments (blood centers) on a pure consumables basis with no capital equipment required.
Product overview
Hemanext offers a unified medical device product called Hemanext ONE, which is the first and only FDA-authorized and CE-marked blood storage system for oxygen-controlled storage of red blood cells. The system consists of two integrated components: the Oxygen Reduction Bag (ORB) that deoxygenates blood during processing, and the Hemanext Storage Bag (HSB) that maintains hypoxic conditions throughout storage. Together, these components preserve red blood cell quality, metabolism, and function for up to 42 days.
Differentiator
Problem solved
Functional benefit
Brands
- Hemanext ONE: First and only FDA-authorized and CE-marked blood storage system that processes and stores red blood cells under oxygen-controlled conditions. The system includes the Oxygen Reduction Bag (ORB) and Hemanext Storage Bag (HSB) components.
Products and services
- Hemanext ONE System A first-in-class FDA-authorized and CE-marked disposable medical device system for processing and storing red blood cells under oxygen-controlled (hypoxic) conditions. The system comprises an Oxygen Reduction Bag (ORB) that removes oxygen and carbon dioxide from RBCs in approximately 3 to 3.5 hours using an iron-based sorbent layer, plus a Hemanext Storage Bag (HSB) with double-wall design that prevents oxygen ingress during 42-day refrigerated storage. Sold to blood establishments (blood centers) on a per-unit consumables basis.
Quantifiable outcome
- In human kidney perfusion model, oxygen-controlled RBC demonstrated 68% increased oxygen diffusion capacity and 20% increased renal respiratory rate vs conventional RBC
- +5 more outcomes
Companies that use Hemanext
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Hemanext technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Hemanext partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- OneBloodcoreStrategic production partnership with OneBlood, one of the nation's largest independent blood centers, marking a significant milestone in Hemanext's U.S. commercial expansion. OneBlood will begin production of hypoxic RBCs using Hemanext ONE at all three of its blood processing facilities located in Charlotte, North Carolina; St. Petersburg, Florida; and Orlando, Florida. OneBlood serves approximately 250+ hospitals across Florida, Georgia, and the Carolinas, supplying ~900,000 RBC units annually (~7% of U.S. national blood supply).
- Hemara BiocoreExclusive distribution agreement with Hemara Bio (Dubai, UAE) covering the Gulf Cooperation Council (GCC) region — UAE, Qatar, Kuwait, and Saudi Arabia. The partnership addresses increasing need for safe and efficient blood transfusions in a region where hemoglobinopathies (sickle cell disease, thalassemia) are prevalent. Hemara Bio brings local market expertise and distribution infrastructure.
- Vitalant Innovation CenterminorHemanext collaborates with Vitalant's Innovation Center to accelerate development and deployment of new blood safety solutions. This partnership supports research collaboration and product development in addition to Vitalant's investment.
Scale indicators6 records
Recent moves7 records
Expansion highlights8 records
Hemanext competitors and assessment
Company assessmentBroad incumbents
- Fresenius Kabi: Fresenius Kabi manufactures blood collection sets, storage bags, and transfusion medical devices. Comparable to Hemanext as an established supplier of disposable blood storage and processing products to blood centers and hospitals.
- Terumo Blood and Cell Technologies: Terumo BCT (a Terumo subsidiary) is a major incumbent in blood component collection, processing, and storage equipment, including apheresis systems. Comparable to Hemanext as a broader blood banking and transfusion medicine technology player with overlapping hospital/customer base.
- Haemonetics: Haemonetics is a global medical device company focused on blood and plasma component collection, apheresis, and hospital software. Comparable to Hemanext given shared customer base of blood centers and hospitals and adjacent product portfolio in blood processing.
- Grifols: Grifols is a global blood products and transfusion diagnostics company, operating blood donor centers and producing plasma-derived therapies and blood typing reagents. Comparable to Hemanext through shared involvement in the blood banking and transfusion medicine supply chain.
- Immucor: Immucor is a transfusion diagnostics company that provides blood bank reagents and instruments (immunohematology). Hemanext board member Geoff Crouse is a former COO of Immucor. Comparable as a focused transfusion/blood bank supplier.
- Ortho Clinical Diagnostics: Ortho Clinical Diagnostics provides immunohematology and blood bank testing systems to hospitals and blood centers globally. Comparable to Hemanext as an established vendor in the blood bank/transfusion medicine space serving the same end customers.
- Bio-Rad Laboratories: Bio-Rad's Life Science and Clinical Diagnostics segments include blood bank quality controls and immunohematology reagents. Comparable as an incumbent supplier serving the blood banking customer base that Hemanext also targets.
Direct peers
- MacoPharma: MacoPharma is a leading European manufacturer of blood collection, processing, and storage bags for transfusion medicine. It is directly comparable to Hemanext as both companies supply disposable blood storage bag systems to blood centers and hospitals globally.
- Cerus Corporation: Cerus develops the INTERCEPT pathogen reduction system for platelets and plasma, used by blood centers globally. Comparable to Hemanext as a blood safety/quality-focused medical device company selling disposable systems to blood establishments with value-based reimbursement.
Emerging players
- Quotient Limited: Quotient develops transfusion diagnostics including the MosaiQ blood bank testing platform. Comparable to Hemanext as a focused transfusion medicine diagnostics/tools company serving blood centers and hospital transfusion services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Hemanext compliance and trust
Trust signalCompliance3 records
Hemanext financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hemanext leadership team
Management profileNumber of profiles
Profiles7 records
Hemanext funding detail
Funding detailFunding overview
Funding rounds10 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hemanext M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hemanext
What does Hemanext do?
Hemanext develops and manufactures the Hemanext ONE System, a first-in-class FDA-authorized and CE-marked disposable medical device that processes and stores red blood cells under oxygen-controlled (hypoxic) conditions. The system consists of an Oxygen Reduction Bag (ORB) that deoxygenates RBCs in approximately 3 to 3.5 hours and a Hemanext Storage Bag (HSB) that maintains hypoxic conditions throughout the 42-day refrigerated shelf life, preserving RBC metabolism, deformability, and post-transfusion recovery. The company sells disposable kits directly to blood establishments (blood centers) on a pure consumables basis with no capital equipment required.
Is Hemanext a public or private company?
Hemanext is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hemanext founded?
Hemanext was founded in 2006. It employs 51 to 100 people.
Where is Hemanext based?
Hemanext is headquartered in Lexington, United States, in the North America region.
How does Hemanext make money?
Two revenue lines are on record. Hemanext ONE Disposable Kit Sales are the primary driver. The others are hypoxic Red Blood Cell Supply.
Who are Hemanext's main competitors?
Broad incumbents on record are Fresenius Kabi, Terumo Blood and Cell Technologies, Haemonetics, Grifols, Immucor, Ortho Clinical Diagnostics and Bio-Rad Laboratories. Direct peers are MacoPharma and Cerus Corporation. Quotient Limited is listed as an emerging player.
Does Hemanext have an API?
No public API is recorded for Hemanext.
What industry is Hemanext in?
Hemanext's product category is Blood Storage Medical Devices. Its primary akta.pro industry code is HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology, with a secondary code of HLAAAJAC, Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors). Its NAICS code is 42421 and its SIC code is 5047.